(1)

Commission Delegated Regulation (EU) No 1062/2014 (2) establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes hexaflumuron.

(2)

Hexaflumuron has been evaluated in accordance with Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council (3) for use in product-type 18, insecticides, acaricides and products to control other arthropods, as defined in Annex V to that Directive, which corresponds to product-type 18, as defined in Annex V to Regulation (EU) No 528/2012.

(3)

Portugal was designated as evaluating competent authority and submitted the assessment report, together with its recommendations, to the Commission on 11 July 2011 in accordance with paragraphs 4 and 6 of Article 14 of Commission Regulation (EC) No 1451/2007 (4).

(4)

In accordance with Article 7(1)(b) of Delegated Regulation (EU) No 1062/2014, the opinion of the European Chemicals Agency was formulated on 3 December 2014 by the Biocidal Product Committee, having regard to the conclusions of the evaluating competent authority.

(5)

According to that opinion, biocidal products used for product-type 18 and containing hexaflumuron may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC provided that certain conditions concerning its use are complied with.

(6)

It is therefore appropriate to approve hexaflumuron for use in biocidal products for product-type 18 subject to compliance with certain specifications and conditions.

(7)

The opinion concludes that the characteristics of hexaflumuron render it very persistent (vP), very bioaccumulative (vB) and toxic (T) in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council (5).

(8)

Since, pursuant to Article 90(2) of Regulation (EU) No 528/2012, substances for which the Member States' evaluation has been completed by 1 September 2013 should be approved in accordance with Directive 98/8/EC, the period of approval should be 5 years in accordance with the practice established under that Directive.

(9)

For the purposes of Article 23 of Regulation (EU) No 528/2012 however, hexaflumuron meets the conditions of Article 10(1)(a) and (d) of that Regulation and should therefore be considered a candidate for substitution.

(10)

Furthermore, pursuant to point 10 of Annex VI to Regulation (EU) No 528/2012, the competent authorities should also evaluate whether the conditions of Article 5(2) can be satisfied to decide if a biocidal product containing hexaflumuron can be authorised or not.

(11)

Since hexaflumuron meets the criteria for being very persistent (vP), very bioaccumulative (vB) and toxic (T) in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006, treated articles treated with or incorporating hexaflumuron should be appropriately labelled when placed on the market.

(12)

A reasonable period should be allowed to elapse before an active substance is approved, in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.

(13)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,